Claims for Patent: 9,427,448

Summary for Patent: 9,427,448

Title:	Methods of treating, reducing the incidence of, and/or preventing ischemic events
Abstract:	Methods of treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor. The method may further comprise administering an additional therapeutic agent to the patient, the additional therapeutic agent comprising a P2Y.sub.12 inhibitor. Pharmaceutical compositions useful for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI. The pharmaceutical compositions comprise cangrelor. Methods of preparing a pharmaceutical composition for treating, reducing the incidence of, and/or preventing an ischemic event in a patient undergoing PCI, comprising admixing cangrelor with one or more pharmaceutically acceptable excipients. An ischemic event may include stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality.
Inventor(s):	Arculus-Meanwell; Clive Arthur (Bernardsville, NJ), Skerjanec; Simona (Basel, CH), Prats; Jayne (Carlisle, MA)
Assignee:	The Medicines Company (Parsippany, NJ)
Application Number:	13/792,056
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for patent 9,427,448
Patent Claims:	1. A method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing percutaneous coronary intervention (PCI), comprising administering to the patient a pharmaceutical composition comprising cangrelor; wherein the pharmaceutical composition is administered intravenously as a 30 .mu.g/kg bolus before the start of PCI, and then is administered intravenously as a continuous infusion at an infusion rate of 4 .mu.g/kg/min after administration of the bolus for the longer of (a) at least two hours or (b) the duration of the PCI. 2. The method of claim 1, wherein the method treats, reduces the incidence of, or prevents an ischemic event during PCI. 3. The method of claim 1, wherein the method treats, reduces the incidence of, or prevents an ischemic event after PCI. 4. The method of claim 1, wherein the ischemic event is selected from the group consisting of stent thrombosis, myocardial infarction, ischemia-driven revascularization, and mortality. 5. The method of claim 4, wherein the ischemic event is stent thrombosis. 6. The method of claim 5, wherein the stent thrombosis is intraprocedural stent thrombosis. 7. The method of claim 1, wherein the administration of the pharmaceutical composition to the patient is not accompanied by a significant increase in severe bleeding or the need for transfusions. 8. The method of claim 1, wherein the PCI comprises stent implantation. 9. A method of treating, reducing the incidence of, or preventing an ischemic event in a patient undergoing PCI, comprising administering to the patient (i) a pharmaceutical composition comprising cangrelor, and (ii) a P2Y.sub.12 inhibitor; wherein the pharmaceutical composition is administered intravenously as a 30 .mu.g/kg bolus before the start of PCI, and then is administered intravenously as a continuous infusion at an infusion rate of 4 .mu.g/kg/min after administration of the bolus for the longer of (a) at least two hours or (b) the duration of the PCI. 10. The method of claim 9, wherein the method treats, reduces the incidence of, or prevents an ischemic event during PCI. 11. The method of claim 9, wherein the method treats, reduces the incidence of, or prevents an ischemic event after PCI. 12. The method of claim 9, wherein the P2Y.sub.12 inhibitor is selected from the group consisting of clopidogrel, prasugrel, and ticagrelor. 13. The method of claim 12, wherein the P2Y.sub.12 inhibitor is clopidogrel. 14. The method of claim 13, wherein the clopidogrel is administered after administration of the pharmaceutical composition.